Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EW.MX
- Price
- 2242.72
- Stock movement up
- +902.02 (67.28%)
- Company name
- Edwards Lifesciences Corporation
- Exchange
- (MX ,
- Currency
- MXN )
- Sector
- Healthcare >Medical Devices
- Market cap
- 1316.70B
- Ent value
- 1317.08B
- Price/Sales
- 223.78
- Price/Book
- 129.03
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 964.97
- Forward P/E
- -
- PEG
- -
- EPS growth
- 33.56%
- 1 year return (CAGR)
- 37.83%
- 3 year return (CAGR)
- 14.77%
- 5 year return (CAGR)
- 5.27%
- 10 year return (CAGR)
- -
Last updated: 2026-03-09
DIVIDENDS
EW.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 964.97 |
| Price to OCF | 1294.95 |
| Price to FCF | 1646.70 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 223.78 |
| Price to Book | 129.03 |
| EV to Sales | 223.85 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 587.10M |
| EPS (TTM) | 2.35 |
| FCF per share (TTM) | 1.38 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.88B |
| Gross profit (TTM) | 4.60B |
| Operating income (TTM) | 1.62B |
| Net income (TTM) | 1.36B |
| EPS (TTM) | 2.35 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 78.19% |
| Operating margin (TTM) | 27.52% |
| Profit margin (TTM) | 23.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.69B |
| Net receivables | 693.30M |
| Total current assets | 6.36B |
| Goodwill | 1.77B |
| Intangible assets | 1.13B |
| Property, plant and equipment | 1.84B |
| Total assets | 13.27B |
| Accounts payable | 165.00M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.59B |
| Total liabilities | 3.07B |
| Shareholder's equity | 10.21B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 1.02B |
| Capital expenditures (TTM) | 217.20M |
| Free cash flow (TTM) | 799.60M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 13.37% |
| Return on Assets | 10.28% |
| Return on Invested Capital | 12.63% |
| Cash Return on Invested Capital | 7.40% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2248.16 |
| Daily high | 2248.16 |
| Daily low | 2225.98 |
| Daily Volume | 0K |
| All-time high | 2598.85 |
| 1y analyst estimate | - |
| Beta | 1.07 |
| EPS (TTM) | 2.35 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 21 Apr 2026 |
Downside potential
Loading...
Downside potential data
| EW.MX | S&P500 | |
| Current price drop from All-time high | -13.70% | -1.82% |
| Highest price drop | -56.56% | -56.47% |
| Date of highest drop | 26 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -21.77% | -10.84% |
| Avg time to new high | 8 days | 12 days |
| Max time to new high | 1121 days | 1805 days |
COMPANY DETAILS
Marketcap
1316.70B
Marketcap category
Large-cap
Description
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Employees
15800
Website
Investor relations
-
SEC filings
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.
March 9, 2026
Edwards Lifesciences has outperformed the S&P 500 recently, and analysts remain moderately optimistic about the stock’s prospects.
March 9, 2026
If you are wondering whether Edwards Lifesciences is attractively priced at its current level, this article will walk through what the numbers are really saying about the stock. The shares recently cl...
March 8, 2026
Cooper Companies tops Q1 EPS estimates and lifts FY26 outlook as MyDay and MiSight drive growth. Shares slip despite solid margin expansion.
March 6, 2026
CLOV jumped 8% after partnering with Kno2 to become the first payer live on a CMS Aligned Network, enabling real-time patient access to clinical and claims data.
March 5, 2026
RVTY gains from strong diagnostics demand and fast-growing Signals software, but China policy pressure and weak research spending temper near-term growth.
March 4, 2026
ISRG expands in Europe after acquiring da Vinci and Ion distribution across Italy, Spain and Portugal, integrating operations to directly support customers.
March 4, 2026
IRVINE, Calif., February 26, 2026--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and str...
February 26, 2026
Edwards Lifesciences is working with a slightly lower fair value estimate, trimmed from US$97.11 to US$96.46 per share, which puts a finer point on how analysts are thinking about the stock today. Tha...
February 26, 2026
Intuitive Surgical, Edwards and Electromed tap GenAI tailwinds as AI healthcare spending surges, despite industry under performance.
February 24, 2026
Next page